- Home
- LXEO vs BIOA Comparison
LXEO vs BIOA Comparison
Compare LXEO & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXEO
- BIOA
- Stock Information
- Founded
- LXEO 2017
- BIOA 2015
- Country
- LXEO United States
- BIOA United States
- Employees
- LXEO 72
- BIOA N/A
- Industry
- LXEO
- BIOA Biotechnology: Pharmaceutical Preparations
- Sector
- LXEO
- BIOA Health Care
- Exchange
- LXEO Nasdaq
- BIOA Nasdaq
- Market Cap
- LXEO 154.0M
- BIOA 144.1M
- IPO Year
- LXEO 2023
- BIOA 2024
- Fundamental
- Price
- LXEO $2.69
- BIOA $4.04
- Analyst Decision
- LXEO Strong Buy
- BIOA Hold
- Analyst Count
- LXEO 5
- BIOA 4
- Target Price
- LXEO $22.20
- BIOA $5.67
- AVG Volume (30 Days)
- LXEO 892.8K
- BIOA 232.7K
- Earning Date
- LXEO 05-20-2025
- BIOA 05-06-2025
- Dividend Yield
- LXEO N/A
- BIOA N/A
- EPS Growth
- LXEO N/A
- BIOA N/A
- EPS
- LXEO N/A
- BIOA N/A
- Revenue
- LXEO N/A
- BIOA $1,451,000.00
- Revenue This Year
- LXEO N/A
- BIOA N/A
- Revenue Next Year
- LXEO N/A
- BIOA N/A
- P/E Ratio
- LXEO N/A
- BIOA N/A
- Revenue Growth
- LXEO N/A
- BIOA N/A
- 52 Week Low
- LXEO $1.45
- BIOA $2.88
- 52 Week High
- LXEO $19.50
- BIOA $26.62
- Technical
- Relative Strength Index (RSI)
- LXEO 41.96
- BIOA N/A
- Support Level
- LXEO $2.77
- BIOA N/A
- Resistance Level
- LXEO $3.35
- BIOA N/A
- Average True Range (ATR)
- LXEO 0.62
- BIOA 0.00
- MACD
- LXEO -0.09
- BIOA 0.00
- Stochastic Oscillator
- LXEO 0.69
- BIOA 0.00
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.
About BIOA BioAge Labs Inc. Common Stock
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.